JPH10508303A - Moraxellaの主要外層膜蛋白CD - Google Patents
Moraxellaの主要外層膜蛋白CDInfo
- Publication number
- JPH10508303A JPH10508303A JP8513562A JP51356296A JPH10508303A JP H10508303 A JPH10508303 A JP H10508303A JP 8513562 A JP8513562 A JP 8513562A JP 51356296 A JP51356296 A JP 51356296A JP H10508303 A JPH10508303 A JP H10508303A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- antibody
- moraxella
- strain
- immunogenic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000588621 Moraxella Species 0.000 title claims abstract description 27
- 101710164702 Major outer membrane protein Proteins 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 235
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 234
- 239000000203 mixture Substances 0.000 claims abstract description 48
- 230000002163 immunogen Effects 0.000 claims abstract description 47
- 241000588655 Moraxella catarrhalis Species 0.000 claims abstract description 45
- 239000008188 pellet Substances 0.000 claims abstract description 43
- 101710116435 Outer membrane protein Proteins 0.000 claims abstract description 25
- 239000006228 supernatant Substances 0.000 claims abstract description 24
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 244000052616 bacterial pathogen Species 0.000 claims abstract description 13
- 108010052285 Membrane Proteins Proteins 0.000 claims abstract description 8
- 238000005119 centrifugation Methods 0.000 claims abstract description 8
- 239000002699 waste material Substances 0.000 claims abstract description 5
- 108010077805 Bacterial Proteins Proteins 0.000 claims abstract description 4
- 238000001727 in vivo Methods 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 55
- 210000004027 cell Anatomy 0.000 claims description 39
- 229960005486 vaccine Drugs 0.000 claims description 31
- 241000894006 Bacteria Species 0.000 claims description 23
- 239000004094 surface-active agent Substances 0.000 claims description 23
- 238000000605 extraction Methods 0.000 claims description 20
- 230000028993 immune response Effects 0.000 claims description 17
- 241000699670 Mus sp. Species 0.000 claims description 16
- 230000003053 immunization Effects 0.000 claims description 16
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 239000002671 adjuvant Substances 0.000 claims description 13
- 230000000844 anti-bacterial effect Effects 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 244000052769 pathogen Species 0.000 claims description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 11
- 230000003308 immunostimulating effect Effects 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 238000009007 Diagnostic Kit Methods 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000013592 cell lysate Substances 0.000 claims description 7
- 210000000987 immune system Anatomy 0.000 claims description 7
- 239000004202 carbamide Substances 0.000 claims description 6
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims description 5
- 239000013504 Triton X-100 Substances 0.000 claims description 5
- 229920004890 Triton X-100 Polymers 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 230000005847 immunogenicity Effects 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims description 5
- 239000012460 protein solution Substances 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 4
- 210000004408 hybridoma Anatomy 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical class O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 3
- 102000004895 Lipoproteins Human genes 0.000 claims description 3
- 108090001030 Lipoproteins Proteins 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical group O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 3
- -1 amino acid octadecyl ester Chemical class 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 230000028996 humoral immune response Effects 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 230000003381 solubilizing effect Effects 0.000 claims description 3
- DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 claims description 2
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 claims description 2
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 238000010367 cloning Methods 0.000 claims description 2
- 230000006806 disease prevention Effects 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 claims description 2
- 229940007718 zinc hydroxide Drugs 0.000 claims description 2
- 229910021511 zinc hydroxide Inorganic materials 0.000 claims description 2
- 241000288906 Primates Species 0.000 claims 2
- 101100099093 Drosophila melanogaster term gene Proteins 0.000 claims 1
- 101100278182 Mus musculus Dnd1 gene Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 238000012790 confirmation Methods 0.000 claims 1
- 230000021633 leukocyte mediated immunity Effects 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 229920002627 poly(phosphazenes) Polymers 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 abstract description 8
- 229920006008 lipopolysaccharide Polymers 0.000 abstract description 8
- 102000018697 Membrane Proteins Human genes 0.000 abstract description 5
- 239000000356 contaminant Substances 0.000 abstract description 3
- 239000006166 lysate Substances 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 184
- 239000000523 sample Substances 0.000 description 32
- 239000000427 antigen Substances 0.000 description 25
- 102000036639 antigens Human genes 0.000 description 25
- 108091007433 antigens Proteins 0.000 description 25
- 239000000243 solution Substances 0.000 description 15
- 206010033078 Otitis media Diseases 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 239000007983 Tris buffer Substances 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 229960001438 immunostimulant agent Drugs 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000003022 immunostimulating agent Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000004931 aggregating effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000606768 Haemophilus influenzae Species 0.000 description 4
- 230000024932 T cell mediated immunity Effects 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- VHUVBWVDIFVVBI-SNYZSRNZSA-N (2s)-3-(4-hydroxyphenyl)-2-(octadecylamino)propanoic acid;hydrochloride Chemical compound Cl.CCCCCCCCCCCCCCCCCCN[C@H](C(O)=O)CC1=CC=C(O)C=C1 VHUVBWVDIFVVBI-SNYZSRNZSA-N 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- 101150028326 CD gene Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004163 cytometry Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 210000004201 immune sera Anatomy 0.000 description 2
- 229940042743 immune sera Drugs 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003571 opsonizing effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- FCZYGJBVLGLYQU-UHFFFAOYSA-M sodium;2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethanesulfonate Chemical compound [Na+].CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCS([O-])(=O)=O)C=C1 FCZYGJBVLGLYQU-UHFFFAOYSA-M 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000007483 tonsillectomy Methods 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- YNJBLTDKTMKEET-ZLUOBGJFSA-N Cys-Ser-Ser Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O YNJBLTDKTMKEET-ZLUOBGJFSA-N 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 241001529548 Megasphaera cerevisiae Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001676573 Minium Species 0.000 description 1
- 206010062204 Moraxella infection Diseases 0.000 description 1
- 208000031548 Moraxellaceae Infections Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000024035 chronic otitis media Diseases 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- IFQUWYZCAGRUJN-UHFFFAOYSA-N ethylenediaminediacetic acid Chemical compound OC(=O)CNCCNCC(O)=O IFQUWYZCAGRUJN-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 230000016178 immune complex formation Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229940031346 monovalent vaccine Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229940047091 other immunostimulants in atc Drugs 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 108010055837 phosphocarrier protein HPr Proteins 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 241000737598 recombinant Hepatitis B virus Species 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
- C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.Moraxella株または該菌株の機能的類縁物から単離することができる単離 ・精製非変性外層膜蛋白CD。 2.前記Moraxella株におけるCD蛋白の特徴的免疫原性を有する請求項1記 載のCD蛋白。 3.Moraxella株がMoraxella catarrhalisである請求項2記載のCD蛋白。 4.前記菌株が、Moraxella catarrhalis RH408である請求項3記載のCD蛋 白。 5.約70重量%以上の純度を有する請求項1記載のCD蛋白。 6.約95重量%以上の純度を有する請求項5記載のCD蛋白。 7.水溶液の形の請求項2記載のCD蛋白。 8.請求項1記載の外層膜蛋白を免疫的に有効な量で含有する免疫原性組成物 。 9.宿主に対するin vivo投与用のワクチンとして製剤して、CD蛋白を産生 するかあるいは宿主においてCD蛋白と特異的に反応する抗体を誘発することが できる蛋白を産生する病原菌によって引き起こされる疾患に対する予防を行う請 求項8記載の免疫原性組成物。 10.病原菌がMoraxella株である請求項9記載の免疫原性組成物。 11.菌株がMoraxella catarrhalisである請求項10記載の免疫原性組成物 。 12.さらに1以上の他の免疫原性または免疫刺激性材料を有してなる請求項 11記載の免疫原性組成物。 13.1以上の他の免疫刺激性材料が1以上のアジュバントである請求項12 記載の免疫原性組成物。 14.1以上のアジュバントが、リン酸アルミニウム、水酸化アルミニウム、 QS21、Quil Aまたはそれらの誘導体もしくは成分、リン酸カルシウム 、水酸化カルシウム、水酸化亜鉛、糖脂質類縁体、アミノ酸のオクタデシルエス テル、ムラミルジペプチド、リポ蛋白、ポリホスファゼン、ISCOM基質、I SCOPRP、DC−cholならびにDDBAからなる群から選択される請求 項13記載の免疫原性組成物。 15.宿主が霊長類である請求項14記載の免疫原性組成物。 16.霊長類がヒトである請求項15記載の免疫原性組成物。 17.微粒子、カプセル、ISCOMまたはリポソーム製剤として製剤される 請求項9記載の免疫原性組成物。 18.免疫系の特異的細胞または粘膜表面への運搬のために標的分子と組み合 わせた請求項9記載の免疫原性組成物。 19.請求項8記載の免疫原性組成物によって宿主を免疫感作することで産生 することができるMoraxellaの外層膜CD蛋白に特異的な抗体。 20.宿主で免疫応答を発生させる方法において、宿主に請求項8記載の免疫 原性組成物を免疫的に有効な量で投与する段階を有してなる方法。 21.前記免疫応答が、体液性または細胞介在性の免疫応答である請求項20 記載の方法。 22.前記免疫応答が、宿主に対して、CD蛋白を産生するかまたは宿主にお いてCD蛋白と特異的に反応する抗体を誘発することができる蛋白を産生する病 原菌によって引き起こされる疾患の予防を行うものである請求項21記載の方法 。 23.検体中でMoraxella catarrhalis蛋白の外層膜蛋白CDと特異的に反応 する抗体の有無を測定する方法であって、 (a)CD蛋白および該蛋白と特異的に反応する検体中に存在する前記抗体を 有してなる複合体を形成するような条件下で、請求項1記載のCD蛋白と検体と を接触させる段階;ならびに (b)前記複合体の形成を測定する段階 を有してなる方法。 24.検体中のCD蛋白の有無を測定する方法であって、 (a)被験者を、請求項8記載の免疫原性組成物で免疫感作して、CD蛋白に 特異的な抗体を産生する段階、 (b)検体と前記抗体とを接触させて、検体中に存在するCD蛋白と前記CD 蛋白特異抗体を有してなる複合体を形成する段階;ならびに (c)前記複合体の形成を測定する段階 を有してなる方法。 25.検体中のCD蛋白が、 (a)Moraxella catarrhalis株あるいは (b)CD蛋白を産生するかまたは宿主においてCD蛋白と特異的に反応する 抗体を形成することができる蛋白を産生する細菌 の一部である請求項23記載の方法。 26.検体中でCD蛋白と特異的に反応する抗体の有無を測定するための診断 キットであって、 (a)請求項1記載のCD蛋白、 (b)前記CD蛋白と検体とを接触させて、前記CD蛋白および検体中に存在 する前記抗体とを有してなる複合体を形成する手段、ならびに (c)前記複合体の形成を測定する手段 を有してなる診断キット。 27.検体中のCD蛋白の有無を検出するための診断キットであって、 (a)請求項17記載の抗体、 (b)該抗体と検体とを接触させて、CD蛋白およびCD特異抗体を有してな る複合体を形成する手段、ならびに (c)前記複合体の形成を測定する手段 を有してなる診断キット。 28.CD蛋白を産生するかあるいは宿主においてCD蛋白と特異的に反応す る抗体を誘発することができる蛋白を産生する病原菌によって引き起こされる疾 患に対する予防のためのワクチンを製造する方法であって、 請求項8記載の免疫原性組成物を被験宿主に投与して、CD蛋白を産生するか または宿主においてCD蛋白と特異的に反応する抗体を形成することができる蛋 白を産生する病原菌によって引き起こされる疾患に対する予防を行うために該組 成物の各種成分の相対量および該組成物の投与頻度を求める段階;ならびに 前記の所定の投与量および投与頻度に従って被投与宿主に投与するのに好適な 剤型で免疫原性組成物を製剤する段階 を有してなる製造方法。 29.投与宿主がヒトである請求項28記載の方法。 30.Moraxella株からの外層膜蛋白CDに特異的なモノクローナル抗体を形 成する方法であって、 (a)請求項8記載の免疫原性組成物を1匹以上のマウスに投与して、1匹以 上の免疫感作マウスを得る段階、 (b)前記1匹以上の免疫感作マウスからBリンパ球を採取する段階、 (c)前記1匹以上の免疫感作マウスから採取したBリンパ球を骨髄腫細胞と 融合することで、ハイブリドーマを形成する段階、 (d)特定の抗CD蛋白抗体を産生するハイブリドーマをクローニングする段 階、 (e)前記抗CD蛋白抗体産生クローンを培養する段階、ならびに (f)前記培地から抗CD蛋白抗体を単離する段階 を有してなる方法。 31.CD蛋白を産生する菌株の単離・精製外層膜蛋白CDを製造する方法で あって、 (a)前記菌株の細胞塊を取得する段階、 (b)前記細胞塊を破壊して、細胞溶解物を得る段階、 (c)前記細胞溶解物を分別して、第1の上清と第1のペレットを得て、該第 1の上清が実質的に大部分の可溶性細菌蛋白を含有するものである段階、 (d)前記第1の上清を前記第1のペレットから分離する段階、 (e)前記第1のペレットの選択的抽出を行って、該ペレットから実質的に全 ての可溶性蛋白およびCD蛋白以外の膜蛋白を除去して、第2の上清およびCD 蛋白を含む抽出済みペレットを得る段階、 (f)前記第2の上清を前記抽出済みペレットから分離する段階、 (g)前記抽出済みペレットを溶解させて、可溶化抽出物を得る段階、 (h)前記可溶化抽出物を分別して、CD蛋白含有上清と廃棄ペレットを得る 段階;ならびに (i)前記CD蛋白含有上清を廃棄ペレットから分離する段階 を有してなる方法。 32.前記菌株がMoraxella株である請求項31記載の方法。 33.前記菌株が、Moraxella catarrhalisである請求項31記載の方法。 34.前記細胞溶解物をそれの遠心によって分別し、可溶化抽出物をそれの遠 心によって分別する請求項31記載の方法。 35.第1のペレットを選択的に抽出する段階が、1以上の界面活性剤抽出を 有してなる請求項34記載の方法。 36.前記第1のペレットの抽出段階が、複数の界面活性剤抽出を有してなる 請求項35記載の方法。 37.前記抽出済みペレットを、該抽出済みペレットの可溶化を行って可溶化 抽出物を提供するだけの温度および時間で、界面活性剤および可溶化剤を含む緩 衝液に分散させ、その液によって可溶化する請求項35記載の方法。 38.前記緩衝液が約7〜約8.5のpHを有し、界面活性剤を約0.1〜約 2重量%含有し、前記可溶化剤としての尿素を約3〜約8Mで含有する請求項3 7記載の方法。 39.界面活性剤が、トリトンX−100である請求項38記載の方法。 40.前記可溶化を、約40〜約70℃で約10〜約120分間行う請求項3 8記載の方法。 41.引き続きCD含有上清を透析して前記界面活性剤および可溶化剤を除去 して、さらに純粋な非変性形のCD蛋白溶液を得る請求項40記載の方法。 42.Moraxella catarrhalis RH408(ATCC指定番号55637)の確認 特性を有するMoraxella catarrhalis菌株。 43.抗血清の抗Moraxella抗殺菌活性を測定する方法において、 前記抗血清によって請求項40記載の非凝集株の所定数の細胞の補体介在殺菌 を実施する段階、ならびに 前記抗Moraxella抗殺菌活性の尺度として前記抗血清によって殺菌された前記 所定数の細胞の割合を測定する段階 を有してなる方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32858994A | 1994-10-24 | 1994-10-24 | |
US08/328,589 | 1994-10-24 | ||
PCT/CA1995/000604 WO1996012733A1 (en) | 1994-10-24 | 1995-10-23 | Major outer membrane protein cd of moraxella |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10508303A true JPH10508303A (ja) | 1998-08-18 |
JP3534771B2 JP3534771B2 (ja) | 2004-06-07 |
Family
ID=23281593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51356296A Expired - Lifetime JP3534771B2 (ja) | 1994-10-24 | 1995-10-23 | Moraxellaの主要外層膜蛋白CD |
Country Status (15)
Country | Link |
---|---|
US (1) | US6121427A (ja) |
EP (1) | EP0787144B1 (ja) |
JP (1) | JP3534771B2 (ja) |
CN (1) | CN1161376C (ja) |
AT (1) | ATE210678T1 (ja) |
AU (1) | AU706832B2 (ja) |
CA (1) | CA2203540C (ja) |
DE (1) | DE69524626T2 (ja) |
DK (1) | DK0787144T3 (ja) |
ES (1) | ES2169166T3 (ja) |
HK (1) | HK1009453A1 (ja) |
MX (1) | MX9702952A (ja) |
PT (1) | PT787144E (ja) |
RU (1) | RU2186582C2 (ja) |
WO (1) | WO1996012733A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002514657A (ja) * | 1998-05-11 | 2002-05-21 | プロヴァリス・ユーケー・リミテッド | モラクセラ・カタラリス蛋白質 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6335018B1 (en) * | 1995-05-01 | 2002-01-01 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
CA2253942A1 (en) * | 1996-05-10 | 1997-11-20 | Biogen, Inc. | Common gamma chain blocking agents |
US5977337A (en) * | 1997-06-03 | 1999-11-02 | Connaught Laboratories Limited | Lactoferrin receptor genes of Moraxella |
US7105164B1 (en) | 1998-04-07 | 2006-09-12 | Sanofi Pasteur Limited | HIV-specific cytotoxic T-cell responses |
GB9808720D0 (en) * | 1998-04-23 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
US6541616B1 (en) | 1998-10-01 | 2003-04-01 | Antex Biologics Inc. | Moraxella catarrhalis protein, gene sequence and uses thereof |
CA2373262A1 (en) * | 1999-05-24 | 2000-11-30 | Xoma (Us) Llc | Therapeutic uses of bpi protein products in humans with otitis media with effusion |
US7517968B2 (en) * | 2003-07-07 | 2009-04-14 | Syracuse University | Rapid and inexpensive method for the purification of proteorhodopsin |
RU2601158C1 (ru) * | 2015-05-12 | 2016-10-27 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова) | ШТАММЫ ВИДА Streptococcus pneumoniae (ВАРИАНТЫ) И СПОСОБ ПОЛУЧЕНИЯ ИЗ НИХ ПРОТЕКТИВНОЙ БЕЛОКСОДЕРЖАЩЕЙ ФРАКЦИИ, ОБЛАДАЮЩЕЙ ВНУТРИВИДОВОЙ ИММУНОГЕННОЙ АКТИВНОСТЬЮ |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI64813C (fi) * | 1980-12-31 | 1984-01-10 | Ilkka Antero Palva | Foerfarande foer producering av ett utvalt aeggviteaemne och vid foerfarandet anvaenda rekombinantplasmidvektorer |
US5110908A (en) * | 1986-12-31 | 1992-05-05 | Praxis Biologics, Inc. | Haemophilus influenzae peptides and proteins |
DE3715840A1 (de) * | 1987-05-12 | 1988-12-01 | Boehringer Mannheim Gmbh | Fuer ein lytisch wirksames, chimaeres protein kodierende rekombinante dna und ihre verwendung |
US5393658A (en) * | 1987-09-28 | 1995-02-28 | New Horizons Diagnostics Corporation | Immunoassay method for the rapid identification of detergent treated antigens |
ES2056378T3 (es) * | 1989-04-14 | 1994-10-01 | Unilever Nv | Procedimiento de extraccion. |
US5141743A (en) * | 1989-04-27 | 1992-08-25 | University Technologies International, Inc. | Method for isolating and purifying transferrin and lactoferrin receptor proteins and vaccines containing the same |
US5292869A (en) * | 1989-04-27 | 1994-03-08 | The Board Of Governors Of The University | Method for isolating and purifying transferrin and lactoferrin receptor proteins from bacteria and the preparation of vaccines containing the same |
US5552146A (en) * | 1991-08-15 | 1996-09-03 | Board Of Regents, The University Of Texas System | Methods and compositions relating to useful antigens of Moraxella catarrhalis |
DE69423383T2 (de) * | 1993-05-13 | 2000-08-24 | American Cyanamid Co | Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken |
IL111102A0 (en) * | 1993-09-29 | 1994-11-28 | Univ New York State Res Found | Vaccine for branhamella catarrhalis |
US5712118A (en) * | 1993-09-29 | 1998-01-27 | Research Foundation Of State University Of New York | Vaccine for branhamella catarrhalis |
-
1995
- 1995-06-07 US US08/474,394 patent/US6121427A/en not_active Expired - Lifetime
- 1995-10-23 MX MX9702952A patent/MX9702952A/es not_active IP Right Cessation
- 1995-10-23 WO PCT/CA1995/000604 patent/WO1996012733A1/en active IP Right Grant
- 1995-10-23 JP JP51356296A patent/JP3534771B2/ja not_active Expired - Lifetime
- 1995-10-23 ES ES95944810T patent/ES2169166T3/es not_active Expired - Lifetime
- 1995-10-23 EP EP95944810A patent/EP0787144B1/en not_active Expired - Lifetime
- 1995-10-23 AT AT95944810T patent/ATE210678T1/de active
- 1995-10-23 CA CA002203540A patent/CA2203540C/en not_active Expired - Fee Related
- 1995-10-23 CN CNB951969633A patent/CN1161376C/zh not_active Expired - Fee Related
- 1995-10-23 PT PT95944810T patent/PT787144E/pt unknown
- 1995-10-23 RU RU97108362/13A patent/RU2186582C2/ru not_active IP Right Cessation
- 1995-10-23 AU AU36953/95A patent/AU706832B2/en not_active Ceased
- 1995-10-23 DE DE69524626T patent/DE69524626T2/de not_active Expired - Lifetime
- 1995-10-23 DK DK95944810T patent/DK0787144T3/da active
-
1998
- 1998-08-25 HK HK98110194A patent/HK1009453A1/xx not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002514657A (ja) * | 1998-05-11 | 2002-05-21 | プロヴァリス・ユーケー・リミテッド | モラクセラ・カタラリス蛋白質 |
Also Published As
Publication number | Publication date |
---|---|
CN1161376C (zh) | 2004-08-11 |
AU3695395A (en) | 1996-05-15 |
PT787144E (pt) | 2002-06-28 |
US6121427A (en) | 2000-09-19 |
DE69524626T2 (de) | 2002-07-04 |
CN1174559A (zh) | 1998-02-25 |
DK0787144T3 (da) | 2002-01-14 |
CA2203540A1 (en) | 1996-05-02 |
DE69524626D1 (de) | 2002-01-24 |
ES2169166T3 (es) | 2002-07-01 |
CA2203540C (en) | 2005-04-05 |
RU2186582C2 (ru) | 2002-08-10 |
JP3534771B2 (ja) | 2004-06-07 |
MX9702952A (es) | 1997-06-28 |
HK1009453A1 (en) | 1999-09-17 |
ATE210678T1 (de) | 2001-12-15 |
WO1996012733A1 (en) | 1996-05-02 |
EP0787144A1 (en) | 1997-08-06 |
AU706832B2 (en) | 1999-06-24 |
EP0787144B1 (en) | 2001-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4005634B2 (ja) | モラクセラ属菌由来トランスフェリン受容体タンパク質 | |
JP2022078317A (ja) | Staphylococcus aureusに対して免疫化するための組成物 | |
CA2592627C (en) | Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide | |
US6558677B2 (en) | Vaccine against gram negative bacteria | |
KR102393038B1 (ko) | OspA의 돌연변이체 단편 및 이에 관련된 방법 및 용도 | |
TW201223542A (en) | Non-lipidated variants of Neisseria meningitidis ORF2086 antigens | |
JP2009515831A (ja) | ペスト菌(Yersiniapestis)抗原を含む組成物 | |
MX2012000158A (es) | Vacunas y composiciones contra streptococcus pneumoniae. | |
HU211031B (en) | Method for preparation of actinobacillus pleuropneumoniae vaccine | |
JP2021514387A (ja) | ブドウ球菌抗原を含む免疫原性組成物 | |
JP4982009B2 (ja) | ナイセリアワクチン組成物および方法 | |
JPH11507805A (ja) | 非細胞性百日咳ワクチンおよびその製造方法 | |
JPH10508303A (ja) | Moraxellaの主要外層膜蛋白CD | |
JP4236215B2 (ja) | 非型性のヘモフイルス インフルエンザ(Haemophilus influenzae)株用のワクチンとしての精製非型性ヘモフイルス インフルエンザP5蛋白質 | |
JP2001503602A (ja) | 非共通形態型好血菌属の高分子量表面タンパク質 | |
Nikokar et al. | Evaluation of the immune responses following co-administration of PilQ and type b-flagellin from Pseudomonas aeruginosa in the burn mouse model | |
JP2002538169A (ja) | インフルエンザ菌に起因する疾患を防御するための、少なくとも3つの抗原を含む多成分系ワクチン | |
KR970001707B1 (ko) | 약독화 녹농균주 cfcpa 50243을 이용한 녹농균 감염 예방 백신 | |
KR970001709B1 (ko) | 약독화 녹농균주 cfcpa 70018을 이용한 녹농균 감염 예방 백신 | |
JP2013510188A (ja) | 黄色ブドウ球菌に由来する菌血症関連抗原 | |
Hung | The role of novel Neisseria meningitidis antigens in the pathogenesis of infection and their potential as vaccine candidates | |
JPH11506335A (ja) | トランスフェリン受容体遺伝子 | |
JPH02101023A (ja) | オーエスキー病のサブユニットワクチン、及び製造方法 | |
MXPA98002853A (es) | Proteina de receptor de transferrina de moraxella | |
JPH06316533A (ja) | クレブシェラ莢膜多糖ワクチン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031120 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20031120 |
|
RD14 | Notification of resignation of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7434 Effective date: 20031120 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040210 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040310 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080319 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090319 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100319 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110319 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110319 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120319 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130319 Year of fee payment: 9 |